In re EpiPen Direct Purchaser Litig., No. 20-cv-0827 (D. Minn.)

In the EpiPen case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Mylan’s EpiPen, an epinephrine auto-injector used to treat anaphylaxis (i.e. allergic reactions).  The complaint alleges that Mylan paid bribes and kickbacks to pharmacy benefit managers CVS/Caremark, Express Scripts, and OptumRx to engage in anticompetitive conduct that led to artificially inflated prices for the $1 billion a year, life-saving drug.  Claims have been asserted under the Sherman Act and RICO statutes.